Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Males and females, aged 2 to \<18 years~* Hepatitis B surface antigen-positive~* Detectable hepatitis B e (HBe) antigen, and no detectable anti-HBe antibodies~* Alanine aminotransferase (ALT) 1.5 to \<10 times the upper limit of normal at screening and within 8 to 24 weeks prior to screening~* Evidence of the presence of hepatitis B virus DNA at least 4 weeks before screening and \>100,000 copies/mL at screening~Key Exclusion Criteria~* Any prior therapy with entecavir~* At least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent~* Therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within 24 weeks of screening~* Coinfection with HIV, hepatitis C virus, or hepatitis D virus~* Decompensated liver disease~* Liver transplant recipients~* Other forms of acute and chronic conditions which may cause increased ALT levels~* Children who were breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Entecavir (Type: ACTIVE_COMPARATOR): Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response

Based on this trial design, predict the completion outcome and termination type (if applicable).